Weight-management
Study
Randomized trials in Chinese populations.1
Metabolic
Mazdutide
GLP-1/glucagon receptor dual agonist (IBI362)
Clinical development and regulatory status vary by jurisdiction; not an FDA-approved product.
What does it do?
Amino-acid sequence
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
An exact sequence has not been verified for this formulation.
Reference identity · not independently confirmed12
Length33 amino acids
Molecular weight · Da4,563.1 Da
Pharmacokinetics
Reported half-lifeNo verified human estimate3
No numerical curve is shown without an exact compound, formulation and human-route match.
No numerical estimate was found in the checked data or Pep-Pedia profile. A curve would require an unsupported assumption.
What to expect
Study outcomes
GLORY-1 weight reduction
At 48 weeks, mean change was −14.01% with 6 mg versus +0.30% with placebo (treatment-policy estimand) in a Chinese trial population.1
Sponsor report now has a publication
GLORY-2 was published in JAMA in 2026. It studied 9 mg weekly for 60 weeks in Chinese adults with obesity, with or without diabetes.2
Reported timelines
Reference & communityWeeks 1–8; 8–60
Source reports early appetite/GI changes followed by weight loss; individual trajectory varies.12
These are reported timelines, not a prediction of your response.
Doses & schedules
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQSubcutaneous | 4 mg target | Once weekly | GLORY-1 weight-management trialChinese adults with overweight or obesityHuman study | 48 weeks | 1 |
Population Chinese adults with overweight or obesity Context Studied under protocol supervision; this is not a self-administration recommendation. Source dose wording 4 or 6 mg target | |||||
| SubQSubcutaneous | 6 mg target | Once weekly | GLORY-1 weight-management trialChinese adults with overweight or obesityHuman study | 48 weeks | 1 |
Population Chinese adults with overweight or obesity Context Studied under protocol supervision; this is not a self-administration recommendation. Source dose wording 4 or 6 mg target | |||||
| SubQ | 1.5 mg → 3 mg | Once weekly | Weight loss initiation (3mg target)Reference report | 48-60+ weeks for full metabolic benefits based on clinical trials | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction labels include unsupported research-peptide pairings. Source tabs Injectable | |||||
| SubQ | 1.5 mg → 3 mg → 4.5 mg | Once weekly | Weight loss progression (4.5mg target)Reference report | 48-60+ weeks for full metabolic benefits based on clinical trials | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction labels include unsupported research-peptide pairings. Source tabs Injectable | |||||
| SubQ | 2 mg → 4 mg → 6 mg | Once weekly | Weight loss optimization (6mg target)Reference report | 48-60+ weeks for full metabolic benefits based on clinical trials | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction labels include unsupported research-peptide pairings. Source tabs Injectable | |||||
| SubQ | 3 mg → 6 mg → 9 mg | Once weekly | Maximum weight loss (9mg target)Reference report | 48-60+ weeks for full metabolic benefits based on clinical trials | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction labels include unsupported research-peptide pairings. Source tabs Injectable | |||||
| SubQ | 3-4.5 mg weekly | Once weekly | T2D management (mild-moderate)Reference report | 48-60+ weeks for full metabolic benefits based on clinical trials | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction labels include unsupported research-peptide pairings. Source tabs Injectable | |||||
| SubQ | 6-9 mg weekly | Once weekly | T2D with obesity (intensive)Reference report | 48-60+ weeks for full metabolic benefits based on clinical trials | 12 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Interaction labels include unsupported research-peptide pairings. Source tabs Injectable | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- 48-60+ weeks for full metabolic benefits based on clinical trials
- Break
- Medical supervision required - effects diminish gradually after discontinuation
Reported timing
Any time of day, with or without food
Side effects & safety
Gastrointestinal adverse events
GI events were most frequent and mostly mild or moderate in GLORY-1.
1High-dose GI burden
GLORY-2 reported vomiting in 53.1%, nausea in 46.9%, and diarrhea in 39.4% with mazdutide.
2GI and heart-rate effects
Nausea, diarrhea/vomiting, dehydration and pulse increase.
Risk contexts
Pancreatitis, gallbladder disease, pregnancy/lactation and thyroid-cancer/MEN2 concerns need review.
Urgent symptoms
Severe abdominal/back pain, neck symptoms, hypoglycemia, allergy, reduced urine, dehydration or marked mood change.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
12 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Semaglutide
Avoidance reportedOverlapping GLP-1 action.12
Reference report · Pep-Pedia label: Avoid CombinationTirzepatide
Avoidance reportedOverlapping GLP-1 action.12
Reference report · Pep-Pedia label: Avoid CombinationLiraglutide
Avoidance reportedOverlapping GLP-1 action.12
Reference report · Pep-Pedia label: Avoid CombinationInsulin
Caution reportedHypoglycemia risk.12
Reference report · Evidence context: Monitor closelySulfonylureas
Caution reportedHypoglycemia risk.12
Reference report · Evidence context: Monitor closelyOral contraceptives
Caution reportedAbsorption concern; source timing rule unvalidated.12
Reference report · Evidence context: Monitor timingLevothyroxine
Caution reportedAbsorption/thyroid monitoring.12
Reference report · Evidence context: Monitor timingMetformin
Unverified pairingCo-treatment studied in diabetes contexts.12
Reference report · Pep-Pedia label: SynergisticCJC-1295
Unverified pairingMuscle-preservation claim unproven.12
Reference report · Pep-Pedia label: CompatibleIpamorelin
Unverified pairingMuscle-preservation claim unproven.12
Reference report · Pep-Pedia label: CompatibleBPC-157
Unverified pairingGI-protection claim unproven.12
Reference report · Pep-Pedia label: CompatibleOther medicines and research compounds
Not establishedNo clinical interaction study for the exact proposed combination was verified; absence of evidence does not establish compatibility.3
Research contextNo matching interactions. Try another name or filter.
Reconstitution
No universal bacteriostatic-water volume or validated preparation method is established for this entry.3
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia describes preparation for this route; product-specific stability has not been independently verified.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- Source temperature: 2-8°C. · Reported post-preparation interval: 30 days.
The source describes gentle mixing and avoiding vigorous shaking.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite to off-white lyophilized powderReported appearanceClear reconstituted solutionReported appearanceIntact vial seal and labelingReported appearanceProper storage conditions maintainedReported variationSource verificationReported concernClumping, discoloration, or moistureReported concernPersistent cloudiness or particles
12Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Evidence limits
View findings →Research-market product identity, purity and formulation cannot be established from a publication.1
3 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Research findings
Human trialsSource context
Interaction labels include unsupported research-peptide pairings.
Compound identity & other names
A dual receptor agonist studied in Chinese obesity and diabetes populations. Published GLORY trial results are separated from early sponsor announcements.
Clinical development and regulatory status vary by jurisdiction; not an FDA-approved product.
GLP-1/glucagon receptor dual agonist (IBI362)312
Pep-Pedia identity record
33 amino acids · 4,563.1 Da
33-amino acid linear synthetic peptide conjugated to C20 fatty diacid moiety through hydrophilic linker at Lys20Reference description; checked chemical identity takes precedence when available.12
How it may work
GLP-1 satiety/glucose signaling plus glucagon-mediated energy/liver effects.12
GLORY-1 weight reduction
At 48 weeks, mean change was −14.01% with 6 mg versus +0.30% with placebo (treatment-policy estimand) in a Chinese trial population.
1Sponsor report now has a publication
GLORY-2 was published in JAMA in 2026. It studied 9 mg weekly for 60 weeks in Chinese adults with obesity, with or without diabetes.
2Source checks & newer research
GLORY-1: once-weekly mazdutide in Chinese adults
610 participants: week 48 mean weight change −11.0% with 4 mg and −14.01% with 6 mg versus +0.30% placebo. GI events predominated; discontinuation for adverse events1.5%,0.5%,1.0%, respectively. These results concern trial product and population, not arbitrary research vials.
Human randomized phase 3 trial13Research areas and evidence gaps
Weight-management research. Randomized trials in Chinese populations.1
- Research-market product identity, purity and formulation cannot be established from a publication.
Additional uses listed by Pep-Pedia
Weight and metabolic syndrome. Human weight, waist, pressure and lipid findings.12
Type 2 diabetes. Glucose/HbA1c and comparative trials.12
Liver fat and cardiovascular risk. Exploratory markers; disease-event benefit remains separate.12
Community reports Unvalidated
Weight discussions as described by Pep-Pedia.3
No representative survey, independently verified products, or controlled outcomes.
Search coverage and review status
The targeted check identified relevant additional literature or current regulatory information; checked findings are separated from retained bibliography-only references.
- Checked
- 2026-10-12
- Search
- mazdutide 2026 DREAMS GLORY trial site:pubmed.ncbi.nlm.nih.gov
- Catalog
- Pep-Pedia ↗ · 9 listed references retained
- Targeted search, not an exhaustive systematic review.
- Bibliography-only entries are retained for traceability and are not treated as verified findings.
AI-prepared summaries. Independent medical editorial review is pending.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
Number of responses to this question: not disclosed.
Age range
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
Number of responses to this question: not disclosed.
Effectiveness
Number of responses to this question: not disclosed.
Side effects
Number of responses to this question: not disclosed.
Dosage frequency
Number of responses to this question: not disclosed.
Would recommend
Number of responses to this question: not disclosed.
How discovered
Number of responses to this question: not disclosed.
Source & limitations
The source displays “45 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
References
Original sources and review status. Open a reference to read its summary.
1GLORY-1 Phase 3 Trial - NEJM (2025)Abstract checked
AI-PREPARED SUMMARY
GLORY-1: 610 participants, 4 or 6 mg weekly. Treatment-policy mean weight change at 48 weeks was −11.00% or −14.01%, versus +0.30% placebo.
GLORY-1 weight reduction
At 48 weeks, mean change was −14.01% with 6 mg versus +0.30% with placebo (treatment-policy estimand) in a Chinese trial population.
Pep-Pedia bibliography · Checked 2026-10-12
2GLORY-2: 9-mg mazdutide randomized clinical trialAbstract checked
AI-PREPARED SUMMARY
Peer-reviewed 2026 phase 3 trial studied 9 mg weekly for 60 weeks; vomiting, nausea and diarrhea were common.
Sponsor report now has a publication
GLORY-2 was published in JAMA in 2026. It studied 9 mg weekly for 60 weeks in Chinese adults with obesity, with or without diabetes.
Additional research · Checked 2026-10-12
3Pep-Pedia: Mazdutide — community referenceCommunity source checked
AI-PREPARED SUMMARY
Accessed October 12, 2026. Secondary descriptions and bibliography; community schedules are unvalidated reports, not recommendations.
4GLORY-2 Phase 3 Trial (2025)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports 20.1% weight loss at 9 mg versus 2.8% with placebo in a non-diabetic subgroup at week 60.
Reported population / model
462 Chinese adults with obesity (BMI ≥30)
Reported study details
60 weeks · 9mg dose
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5DREAMS-3 Phase 3 Trial - Head-to-Head vs Semaglutide (2025)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: A combined HbA1c/weight target was reportedly reached by 48.0% versus 21.0% on the semaglutide comparator; comparator dose matters.
Reported population / model
349 Chinese adults with T2D and obesity
Reported study details
32 weeks · Mazdutide vs Semaglutide
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Systematic Review & Meta-Analysis - Frontiers (2024)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Seven trials reportedly showed 6.22 percentage points more weight loss than placebo; gastrointestinal symptoms were the main reported adverse events.
Reported population / model
7 RCTs
Reported study details
680 participants · 4-24 weeks · Meta-analysis of efficacy and safety
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Phase 2 T2D Trial - Diabetes Care (2024)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: At 20 weeks, HbA1c reductions were reported as 1.41–1.67 points versus 0.03 with placebo, with weight loss up to 7.1%.
Reported population / model
Chinese adults with T2D
Reported study details
20 weeks · 3mg, 4.5mg, 6mg doses vs placebo and dulaglutide
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
8Phase 1b High-Dose Safety Trial - eClinicalMedicine (2022)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The 24-person early trial reported 11.7% weight loss in the 9 mg cohort and no serious events; small samples cannot exclude uncommon harms.
Reported population / model
24 Chinese adults with overweight/obesity
Reported study details
12 weeks · 9mg and 10mg doses
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
9Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 TrialLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
10Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trialLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
11A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesityLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
12Pep-Pedia: Mazdutide — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12
13GLORY-1: once-weekly mazdutide in Chinese adultsPrimary source checked
AI-PREPARED SUMMARY
610 participants: week 48 mean weight change −11.0% with 4 mg and −14.01% with 6 mg versus +0.30% placebo. GI events predominated; discontinuation for adverse events1.5%,0.5%,1.0%, respectively. These results concern trial product and population, not arbitrary research vials.
GLORY-1: once-weekly mazdutide in Chinese adults
610 participants: week 48 mean weight change −11.0% with 4 mg and −14.01% with 6 mg versus +0.30% placebo. GI events predominated; discontinuation for adverse events1.5%,0.5%,1.0%, respectively. These results concern trial product and population, not arbitrary research vials.
Additional primary-source check · Checked 2026-10-12